
    
      PRIMARY OBJECTIVES:

      To determine the recommended Phase II dose (RP2D) for ibrutinib in combination with
      lenalidomide in patients with myelodysplastic syndrome (MDS).

      SECONDARY OBJECTIVES:

      To do an early assessment of the activity of the combination of ibrutinib and lenalidomide in
      patients with MDS.

      TERTIARY OBJECTIVES:

      To examine the pharmacodynamic and biological effects of the combination of ibrutinib and
      lenalidomide in MDS.
    
  